Fat Burning+ IV Drip

About This IV

Fat Burning+ is a precision metabolic IV formula engineered around the three rate-limiting biochemical steps that determine the rate of body fat oxidation: (1) fatty acid mobilisation from adipose tissue into circulation (lipolysis), (2) transport of long-chain fatty acids across the inner mitochondrial membrane (carnitine shuttle), and (3) hepatic lipid processing and export (methionine-dependent methylation and phosphatidylcholine synthesis). By delivering the specific cofactors, substrates, and enzyme activators for each of these steps intravenously — bypassing intestinal absorption limits and hepatic first-pass metabolism — Fat Burning+ achieves plasma concentrations of these compounds that are pharmacologically impossible to attain orally. L-Carnitine (1250mg combined) is the central and most clinically validated compound in this formula. Long-chain fatty acids (palmitate C16:0, stearate C18:0, oleate C18:1) — the primary stored form of body fat — cannot cross the inner mitochondrial membrane in their free form. They must be conjugated with carnitine by carnitine palmitoyltransferase I (CPT1, the rate-limiting enzyme of beta-oxidation) to form acylcarnitine, transported across the membrane by the carnitine-acylcarnitine translocase (CACT), and then released as acyl-CoA for beta-oxidation by CPT2. In a state of carnitine insufficiency — which is common in caloric restriction (carnitine biosynthesis requires adequate lysine and methionine), vegetarian/vegan diets (carnitine is exclusively found in animal foods), and in overweight states where carnitine transport capacity is exceeded — CPT1 becomes substrate-limited and fatty acid oxidation rate falls despite abundant mitochondria. IV carnitine at 1250mg achieves plasma carnitine concentrations of 400–800 µmol/L, far exceeding the CPT1 Km (affinity constant), ensuring CPT1 operates at Vmax (maximum velocity) regardless of the patient's carnitine status. Clinical trials of IV carnitine supplementation demonstrate 20–35% increases in fat oxidation rate as measured by respiratory quotient (RQ) reduction and 13C-labelled palmitate oxidation. Methionine (500mg) addresses the hepatic component of fat metabolism — a frequently overlooked but clinically critical determinant of body composition. The liver is the primary organ for fatty acid processing: free fatty acids delivered from adipose tissue lipolysis are either beta-oxidised for energy, re-esterified to triglycerides for VLDL export, or (in pathological states) accumulate as hepatic steatosis (fatty liver). Methionine is the precursor to S-adenosylmethionine (SAM) — the universal methyl donor in all biological methylation reactions. In the context of lipid metabolism, SAM provides the methyl groups for phosphatidylcholine synthesis via the PEMT (phosphatidylethanolamine N-methyltransferase) pathway: phosphatidylethanolamine + 3 SAM → phosphatidylcholine + 3 SAH. Phosphatidylcholine is an essential structural component of VLDL particles — without adequate hepatic phosphatidylcholine, the liver cannot export triglycerides as VLDL, leading to triglyceride accumulation in hepatocytes (fatty liver) and reduced systemic fatty acid clearance. IV methionine at 500mg rapidly expands the hepatic SAM pool, enhancing PEMT flux and VLDL export capacity — effectively 'unjamming' the hepatic lipid processing bottleneck and allowing adipose-derived fatty acids to be efficiently exported and cleared. Niacinamide B3 (100mg) targets the NAD⁺/NADH ratio — the master regulator of metabolic fuel selection between fat and carbohydrate oxidation. NAD⁺ is the electron acceptor for the key fat-oxidising dehydrogenases: beta-hydroxyacyl-CoA dehydrogenase in beta-oxidation, isocitrate dehydrogenase and alpha-ketoglutarate dehydrogenase in the Krebs cycle, and malate dehydrogenase. When the NAD⁺ pool is depleted (NADH:NAD⁺ ratio elevated), these dehydrogenases slow, fat oxidation rate falls, and pyruvate is diverted to lactate (Cori cycle) rather than acetyl-CoA. Niacinamide (the amide form of niacin, which unlike nicotinic acid does not cause flushing) is a direct NAD⁺ precursor via the salvage pathway: niacinamide → NMN → NAD⁺ via NAMPT and NMNAT enzymes. Restoring NAD⁺ availability increases beta-oxidation flux and Krebs cycle throughput simultaneously, amplifying the fat-burning effect of L-Carnitine-mediated fatty acid delivery. Vitamin C (4000mg) serves three distinct roles in this formula beyond general antioxidant protection. First, it is an obligate cofactor for carnitine biosynthesis — the final two steps of the carnitine biosynthetic pathway (butyrobetaine hydroxylation by gamma-butyrobetaine dioxygenase, BBOX) require Vitamin C as the electron donor. Even with adequate oral carnitine, Vitamin C deficiency impairs endogenous carnitine synthesis from lysine and methionine. Second, it supports catecholamine synthesis — dopamine beta-monooxygenase (the enzyme converting dopamine to noradrenaline) is Vitamin C-dependent; noradrenaline is the primary lipolytic hormone binding adipocyte beta-adrenergic receptors to activate hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL). Third, it regenerates tetrahydrobiopterin (BH4) — the cofactor for tyrosine hydroxylase in catecholamine synthesis — ensuring the sympathoadrenal axis that drives thermogenesis remains active. Dexpanthenol B5 (530mg combined) is converted to pantothenate and then Coenzyme A — the universal acyl group carrier for both fatty acid synthesis (malonyl-CoA pathway) and beta-oxidation (acyl-CoA pathway). CoA is required at every acylation step of beta-oxidation, and the intracellular acyl-CoA/CoA ratio is a key determinant of CPT1 activity (palmitoyl-CoA inhibits CPT1 via competition with free CoA). Adequate CoA (via B5) ensures that beta-oxidation intermediates are efficiently processed and do not accumulate to inhibit CPT1. N-Acetylcysteine (250mg) provides the rate-limiting cysteine for glutathione synthesis — critical in this formula because beta-oxidation generates FADH₂ and NADH at rates that can overwhelm the mitochondrial electron transport chain, producing superoxide and requiring robust antioxidant buffering to prevent lipid peroxidation of the mitochondrial inner membrane. Magnesium Chloride (1000mg) activates over 300 fat-metabolism-relevant enzymes including: citrate synthase (Krebs cycle entry), fatty acid synthetase (lipogenesis modulation), and the Na/K-ATPase pump that maintains the membrane potential driving mitochondrial ATP synthesis. Magnesium also activates AMPK (AMP-activated protein kinase) indirectly via its role in the ATP:AMP ratio — AMPK is the master switch for fat oxidation, activating CPT1 while simultaneously inhibiting malonyl-CoA synthesis (malonyl-CoA is the allosteric inhibitor of CPT1 in the fed state). The full B-vitamin support stack (Thiamine B1 200mg, Pyridoxine B6 100mg, Hydroxocobalamin B12 5mg, Methylfolate B9 0.5mg, Selenium 0.1mg) ensures no cofactor deficiency limits any enzymatic step between fatty acid mobilisation and CO₂/H₂O final products.